BioSante Announces FDA Orphan Drug Designation For GVAX Chronic Myeloid Leukemia Cancer Vaccine
BioSante Pharmaceuticals, Inc. has announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia (CML) from the FDA’s Office of Orphan Products Development. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease that affects almost 200,000 Americans. Orphan drug designation qualifies the sponsor of the product for tax credits and seven years of marketing exclusivity.
Read the full story here
-
Reata’s RTA 402 receives orphan drug status from FDA
FDA grants orphan drug status to treatment for cancer
FDA accepts Cell Therapeutics NDA for cancer drug
OncoGenex metastatic prostate cancer drug candidate given “fast track designation”
Sirtex Announces Creation of Centers of Excellence Program
